Accelerating the Future of


We are a clinical-stage, globally active biotechnology company developing LAG-3 immunotherapies for cancer and autoimmune diseases. We have a number of active collaborations underway with various corporations and academic institutions and consider them an integral part of our business including:

  • Clinical trial collaboration and supply agreements with MSD (Merck US) and Merck KGaA (Darmstadt, Germany)
  • License agreements with Novartis (LAG525), GlaxoSmithKline (GSK’781) and EOC Pharma (eftilagimod alpha in Greater China). The clinical-stage asset GSK’781 is being transitioned back to Immutep as the licensing agreement has been terminated with an effective date of 30 May 2024.
  • Additional collaborations or agreements with Labcorp, Maria Skłodowska-Curie National Research Institute, Cardiff University, and Monash University.

Collaboration and Licensing Opportunities

We welcome potential collaboration or licensing opportunities in oncology that would complement our existing portfolio and technology platform. We are also interested in novel immunotherapy opportunities in other disease areas. If you are interested in a collaboration, licensing (in- and out-licensing) or partnership discussion, we welcome you to contact us directly.

For information on partnerships, collaboration opportunities, and general licensing enquiries for Immutep, please email us at: